Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacopeia Identifies Lead Compound for Bristol-Myers Squibb


PRINCETON, NJ--Pharmacopeia reached a milestone in its collaboration with Bristol-Myers Squibb on inflammatory and immunological disease targets when it identified a lead compound, the company announced last week. Bristol-Myers made a cash payment to Pharmacopeia for the achievement.

In just four months, "using our large, rationally designed libraries of small molecules and high-throughput screening, we were able to identify a lead compound against a challenging target and receive confirmation of activity from Bristol-Myers," Pharmacopeia President Joseph Mollica said.

Pharmacopeia combines small molecule combinatorial chemistry with high-throughput screening for drug discovery. Using a proprietary tagging technology, Eclips, the company generates large libraries of diverse, easily identifiable small molecules. With high-throughput screening, it tests compounds in a full complement of assays, including enzyme, receptor binding, and cell-based assays.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.